Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for ...

Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for the ...

Zimislecel, Vertex’s islet cell therapy, remains on track for Phase 3 completion in 2025, with regulatory submissions expected in 2026. China’s new tariffs just reignited the same market ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Despite the setback, Vertex continues to develop another T1D therapy, zimislecel, which is currently being investigated in a Phase III trial (NCT04786262). Zimislecel is administered alongside ...

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to trigger sufficient levels of insulin production in a phase 1/2 trial.

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge loss for Vertex given that the company has a more advanced type 1 diabetes ...